Codexis to Present at the 25th International Molecular Medicine Tri-Conference
“Molecular diagnostics next generation sequencing (NGS) assays are critically dependent on efficient conversion of low-concentration DNA samples to sequencing-capable fragments via adapter ligation,” said Nicols. “Codexis has developed an engineered DNA ligase to achieve exceptional conversion of low-concentration input DNA with improved reaction kinetics relative to commercially available T4 ligase, while maintaining low adapter dimerization activity. The Codexis Performance DNA Ligase is ideally suited for NGS IVD applications, where it will improve assay sensitivity and increase workflow flexibility and robustness. We’re delighted to discuss our new high-performance enzyme with the many thought leaders in diagnostics attending this conference.”
Since its debut in 1993, the annual
To the extent that statements contained in this press release are not descriptions of historical facts regarding
LHA Investor Relations
Source: Codexis, Inc.